Carcinoid syndrome historical perspective: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Carcinoid syndrome}} | {{Carcinoid syndrome}} | ||
{{CMG}} | {{CMG}}{{AE}}{{PSD}} | ||
==Overview== | ==Overview== | ||
| Line 17: | Line 16: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Revision as of 20:20, 16 September 2015
|
Carcinoid syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carcinoid syndrome historical perspective On the Web |
|
American Roentgen Ray Society Images of Carcinoid syndrome historical perspective |
|
Risk calculators and risk factors for Carcinoid syndrome historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Historical Perspective
Carcinoids were first characterized in 1907 by Siegfried Oberndorfer, a German pathologist at the University of Munich, who coined the term karzinoide, or "carcinoma-like", to describe the unique feature of behaving like a benign tumour despite having a malignant appearance microscopically. The recognition of their endocrine-related properties were later described by Gosset and Masson in 1914, and these tumours are now known to arise from the enterochromaffin (EC) and enterochromaffin-like (ECL) cells of the gut.